We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+18.41%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
+$36.6M
Cap. Flow
+$22.8M
Cap. Flow %
13.88%
Top 10 Hldgs %
53.05%
Holding
50
New
5
Increased
29
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.39M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$4.21M
3
LLY icon
Eli Lilly
LLY
+$3.54M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$3.38M
5
OPCH icon
Option Care Health
OPCH
+$3.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$4.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.52M
3
CI icon
Cigna
CI
+$4.49M
4
COR icon
Cencora
COR
+$4.25M
5
GILD icon
Gilead Sciences
GILD
+$3.61M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$317B
$17.6M 10.74%
133,741
+68,066
+104% +$8.39M
LLY icon
2
Eli Lilly
LLY
$1.06T
$16.2M 9.84%
20,778
+4,973
+31% +$3.54M
UNH icon
3
UnitedHealth
UNH
$367B
$11.4M 6.94%
23,041
+4,633
+25% +$2.36M
TMO icon
4
Thermo Fisher Scientific
TMO
$214B
$8.83M 5.37%
15,186
+3,771
+33% +$2.12M
NBIX icon
5
Neurocrine Biosciences
NBIX
$16.2B
$6M 3.65%
43,480
+30,863
+245% +$4.21M
HRMY icon
6
Harmony Biosciences
HRMY
$2.26B
$5.71M 3.47%
170,000
+25,000
+17% +$802K
SYK icon
7
Stryker
SYK
$129B
$5.42M 3.3%
15,154
+2,352
+18% +$791K
AMGN icon
8
Amgen
AMGN
$219B
$5.37M 3.27%
18,891
+2,868
+18% +$839K
ABBV icon
9
AbbVie
ABBV
$431B
$5.34M 3.25%
29,346
+8,150
+38% +$1.4M
BSX icon
10
Boston Scientific
BSX
$71.4B
$5.3M 3.23%
77,401
+12,595
+19% +$810K
REGN icon
11
Regeneron Pharmaceuticals
REGN
$79.5B
$5.19M 3.16%
5,393
+1,414
+36% +$1.34M
COR icon
12
Cencora
COR
$63.2B
$4.96M 3.02%
20,426
-18,499
-48% -$4.25M
MOH icon
13
Molina Healthcare
MOH
$10B
$4.93M 3%
12,000
-500
-4% -$194K
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$123B
$4.72M 2.87%
11,295
+2,165
+24% +$915K
OPCH icon
15
Option Care Health
OPCH
$3.54B
$4.46M 2.71%
132,895
+95,672
+257% +$3.1M
ELV icon
16
Elevance Health
ELV
$84.9B
$3.84M 2.33%
7,400
-2,100
-22% -$1.04M
GILD icon
17
Gilead Sciences
GILD
$162B
$3.81M 2.32%
52,000
-46,974
-47% -$3.61M
DXCM icon
18
DexCom
DXCM
$31.3B
$3.65M 2.22%
26,283
+8,226
+46% +$1.03M
MIRM icon
19
Mirum Pharmaceuticals
MIRM
$5.74B
$3.09M 1.88%
+123,000
New +$3.38M
CAH icon
20
Cardinal Health
CAH
$55.7B
$3.08M 1.87%
27,500
-20,500
-43% -$2.21M
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
$2.97M 1.81%
252,307
+203,597
+418% +$2.6M
FUSN
22
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.96M 1.8%
138,836
+13,836
+11% +$165K
IONS icon
23
Ionis Pharmaceuticals
IONS
$9.06B
$2.77M 1.68%
63,791
+39,548
+163% +$1.89M
IMCR icon
24
Immunocore
IMCR
$1.75B
$2.66M 1.62%
40,899
+33,076
+423% +$2.27M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.63M 1.6%
38,050
+25,805
+211% +$1.77M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q1 2024 Portfolio in Review

As of Q1 2024, HealthInvest Partners held 50 positions worth $164M, up 29% from $128M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

HealthInvest Partners deployed $22.8M of net new capital in Q1 2024, opening 5 new positions and adding to 29 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 123,000 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cencora, an estimated $4.25M trimmed.

  • HealthInvest Partners's largest Q1 2024 buy was Mirum Pharmaceuticals: 123,000 shares worth $3.09M.
  • HealthInvest Partners added most to Merck in Q1 2024, an estimated $8.39M increase.
  • HealthInvest Partners's biggest Q1 2024 reduction was Cencora, cutting an estimated $4.25M.
  • HealthInvest Partners fully exited Centene in Q1 2024, selling an estimated $4.6M.
  • HealthInvest Partners's ten largest holdings make up 53% of its $164M portfolio in Q1 2024.
  • HealthInvest Partners opened 5 new positions and closed 6 in Q1 2024.
  • HealthInvest Partners's portfolio value rose 29% quarter-over-quarter to $164M.

Based on HealthInvest Partners's 13F filing for Q1 2024, filed 25 Apr 2024.